BJCT-BIOJECT-needle less injection product Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : BJCT-BIOJECT-needle less injection product

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Michael C. Woodward who wrote (68)	11/6/1997 10:39:00 AM
From: Marc Kahn	of 534

Hambrecht and Quist is already a substantial holder of BJCT with 3,380,300 shares (12.8%). It seems that this number includes some un-exercised warrants (footnote says 1,190,000). << I believe that the presentation to Hambricht & Quist will be a critical point for Bioject. Let's hope H&Q responds favorably.>> I got this info from an SEC filing of 11/4/97 (Form PRE 14A). I have noticed how some posters here manage to get hot links to other pages into their posts. I am not sure how they do this, but I have copied the URL from the SEC filing and hope that it turns into a link. We'll see... edgar-online.com Hey, it worked! Marc Kahn

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next